SLE

Super League to be renamed “Superplanet, Inc.” and become Metaplanet's U.S. Bitcoin treasury platform, backed by the world's third-largest corporate Bitcoin holder with 43,000 BTC

Super League Enterprise, Inc. (SLE) Q2 2026 Earnings Call Transcript

Net Revenue increases 16% sequentially as gross margin expands five percentage points to 41%  Adjusted EBITDA improves approximately 20% year-over-year as Company maintains disciplined cost structure SANTA MONICA, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Super League (Nasdaq: SLE) (the “Company”), an audience intelligence and media activation company trusted by global brands to reach and engage people who play video games across the digital advertising landscape, today announced financial results for the second quarter ended June 30, 2026, reflecting continued operating progress despite a challenging advertising environment.

SANTA MONICA, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Super League (Nasdaq: SLE) (the “Company”), an audience intelligence and media activation company trusted by global brands to reach and influence people who play video games across the digital landscape, announced today that the Company will post its second quarter 2026 financial results before market open on Friday, August 14, 2026. A webinar will be held the same day at 8:30 am Eastern Time to discuss the results and can be accessed using the below dial-in numbers or registration link.

Partnership Unlocks Premium, Audience-First Advergaming Units Across the World's Largest Portfolio of CTV Games and Video Channels Partnership Unlocks Premium, Audience-First Advergaming Units Across the World's Largest Portfolio of CTV Games and Video Channels

SANTA MONICA, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Super League (Nasdaq: SLE) (the “Company”), an audience intelligence and media activation company trusted by global brands to reach and influence people who play video games across the digital landscape, today announced the appointment of Anthony Alexander as Executive Vice President of Revenue, effective June 8, 2026.

Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with this disease while preserving immune function Results demonstrated significant reduction of systemic lupus erythematosus disease activity which continued beyond the 24-week primary endpoint, and were sustained through Week 52 in the nipocalimab 15 mg/kg groupa The ongoing Phase 3 study of nipocalimab is currently recruiting people living with systemic lupus erythematosus – a debilitating autoantibody-driven disease which can lead to systemic organ damage LONDON, June 3, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced nipocalimab met the primary endpoint of decreasing disease activity at 24 weeks as measured by SLE Responder Index 4 (SRI-4)b and continued to demonstrate sustained reduction in disease activity in adults with moderate-to-severe systemic lupus erythematosus (SLE)a through 52 weeks in the Phase 2 JASMINE study as measured by both SRI-4b and Lupus Low Disease Activity State (LLDAS).c In addition, the study results showed greater response versus placebo plus background medicationd in participants who tested positive for lupus-associated autoantibodies, which represents the vast majority (~80%) of people living with SLE.e,1 These findings will be featured in a late-breaking presentation at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress in London and are among the 38 abstracts the Company is presenting across its Rheumatology portfolio.  Nipocalimab is designed to selectively block the neonatal Fc receptor (FcRn), reducing levels of circulating pathogenic immunoglobulin (IgG) autoantibodies and immune complexes associated with inflammation in SLE.2,3 By reducing circulating IgG, including autoantibodies, nipocalimab is designed to target the underlying cause of disease while preserving critical immune functions.4 JASMINE is the first clinical study to demonstrate efficacy of FcRn blockade in SLE and provides clinical, biomarker and pharmacodynamic evidence supporting the continued investigation of nipocalimab as a potential treatment option for this disease.5 A healthcare professional's perspective "The consistent improvements observed across established disease activity measures and reductions in pathogenic immunoglobulin G autoantibodies are encouraging and support the continued investigation of nipocalimab as a targeted treatment approach for people living with systemic lupus erythematosus," said Richard Furie, M.D.

Super League Enterprise (SLE) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

SANTA MONICA, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Super League (Nasdaq: SLE) (the “Company”), an audience intelligence and media activation company trusted by global brands to reach and influence people who play video games across the digital landscape, announced the launch of the Job City by Indeed game, an immersive new experience on Roblox designed to help players explore and build essential workplace skills through interactive, game-based assessments.

President Trump's 12-word remark, “I don't think about Americans' financial situation, I don't think about anybody,” hit the wires, and the reaction showed up in the forgotten corners of the market, where micro-cap turnarounds priced like option contracts ripped higher on May 15 as traders rotated into beaten-down names with operational catalysts already in motion.